

Pathogenic mechanisms in HBV- and HCV-associated h

Nature Reviews Cancer

13, 123-135

DOI: [10.1038/nrc3449](https://doi.org/10.1038/nrc3449)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Significant association between XRCC3 C241T polymorphism and increased risk of hepatocellular carcinoma: a meta-analysis. <i>Tumor Biology</i> , 2013, 34, 3865-3869.	1.8	6
2	Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells. <i>Tumor Biology</i> , 2013, 34, 3397-3405.	1.8	8
3	Tying the knot between cytokine and toll-like receptor signaling in gastrointestinal tract cancers. <i>Cancer Science</i> , 2013, 104, 1139-1145.	3.9	27
4	Epidermal growth factor, its receptor and transforming growth factor- β 1 in the diagnosis of HCV-induced hepatocellular carcinoma. <i>Medical Oncology</i> , 2013, 30, 673.	2.5	12
5	Hepatitis B virus X protein disrupts stress fiber formation and triggers apoptosis. <i>Virus Research</i> , 2013, 175, 20-29.	2.2	11
6	Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling. <i>Genomics</i> , 2013, 101, 238-248.	2.9	22
7	Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation. <i>Carcinogenesis</i> , 2013, 34, 1955-1967.	2.8	88
8	Immunity, inflammation and cancer: a leading role for adenosine. <i>Nature Reviews Cancer</i> , 2013, 13, 842-857.	28.4	612
9	Virus et cancers humains : des virus modaux aux nouvelles étiologies. <i>Revue Francophone Des Laboratoires</i> , 2013, 2013, 37-46.	0.0	1
10	Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. <i>Scientific Reports</i> , 2013, 3, 1555.	3.3	77
11	Substrate Cleavage Profiling Suggests a Distinct Function of <i>Bacteroides fragilis</i> Metalloproteinases (Fragilysin and Metalloproteinase II) at the Microbiome-Inflammation-Cancer Interface. <i>Journal of Biological Chemistry</i> , 2013, 288, 34956-34967.	3.4	25
12	Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus. <i>Virology Journal</i> , 2013, 10, 259.	3.4	51
14	Outcomes following liver resection and clinical pathologic characteristics of hepatocellular carcinoma occurring in patients with chronic hepatitis B and minimally fibrotic liver. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1371-1376.	1.0	12
15	Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. <i>Genomics</i> , 2013, 102, 74-83.	2.9	140
16	Successful Resection of Intracranial Metastasis of Hepatocellular Carcinoma. <i>Case Reports in Gastroenterology</i> , 2013, 7, 182-187.	0.6	3
17	Associations of miR-499 and miR-34b/c Polymorphisms with Susceptibility to Hepatocellular Carcinoma: An Evidence-Based Evaluation. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-8.	1.5	19
18	Response. <i>Journal of the National Cancer Institute</i> , 2013, 105, 668-671.	6.3	0
19	Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis. <i>Seminars in Liver Disease</i> , 2013, 33, 147-156.	3.6	96

#	ARTICLE	IF	CITATIONS
20	Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs. <i>Scientific Reports</i> , 2013, 3, 2739.	3.3	37
21	Emerging Role of High-Mobility Group Box 1 (HMGB1) in Liver Diseases. <i>Molecular Medicine</i> , 2013, 19, 357-366.	4.4	98
22	Association of 5-Methylcytosine and 5-Hydroxymethylcytosine with Mitochondrial DNA Content and Clinical and Biochemical Parameters in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e76967.	2.5	8
23	Is the Oxidative DNA Damage Level of Human Lymphocyte Correlated with the Antioxidant Capacity of Serum or the Base Excision Repair Activity of Lymphocyte?. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-8.	4.0	3
24	Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2014, 2, 61.	3.7	62
25	Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment. <i>Pathogens</i> , 2014, 3, 563-576.	2.8	4
26	Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. <i>World Journal of Gastroenterology</i> , 2014, 20, 11630.	3.3	158
27	Using proteomics to identify the HBx interactome in hepatitis B virus: how can this inform the clinic?. <i>Expert Review of Proteomics</i> , 2014, 11, 59-74.	3.0	18
28	Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. <i>Cancer Cell International</i> , 2014, 14, 83.	4.1	20
29	Outflanking HCV. <i>Nature Immunology</i> , 2014, 15, 6-8.	14.5	4
30	Effect of Antiretroviral HIV Therapy on Hepatitis B Virus Replication and Pathogenicity. <i>Intervirology</i> , 2014, 57, 212-217.	2.8	11
31	CD81-Receptor Associations " Impact for Hepatitis C Virus Entry and Antiviral Therapies. <i>Viruses</i> , 2014, 6, 875-892.	3.3	33
32	Hepatitis B Virus Infection and Immunopathogenesis in a Humanized Mouse Model: Induction of Human-Specific Liver Fibrosis and M2-Like Macrophages. <i>PLoS Pathogens</i> , 2014, 10, e1004032.	4.7	191
33	The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. <i>Cancers</i> , 2014, 6, 79-111.	3.7	82
35	WNT/β-catenin pathway activation in hepatocellular carcinoma: a clinical perspective. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 0, , 49.	5.5	5
36	The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease. <i>International Journal of Molecular Sciences</i> , 2014, 15, 4747-4779.	4.1	23
37	Managing hepatitis B to prevent liver cancer: recent advances. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 409-415.	3.0	3
38	Are human polyomaviruses cofactors for cancers induced by other oncoviruses?. <i>Reviews in Medical Virology</i> , 2014, 24, 343-360.	8.3	26

#	ARTICLE	IF	CITATIONS
39	Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. <i>Clinical and Experimental Immunology</i> , 2014, 176, 102-111.	2.6	10
40	Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2014, 135, 1119-1126.	5.1	57
41	The Pathogenesis of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 545-553.	1.9	45
42	Hepatic Fibrosis and the Microenvironment: Fertile Soil for Hepatocellular Carcinoma Development. <i>Gene Expression</i> , 2014, 16, 77-84.	1.2	56
43	Ablation therapy for hepatocellular carcinoma: past, present and future perspectives. <i>Hepatic Oncology</i> , 2014, 1, 67-79.	4.2	11
44	Differences in Surgical Outcomes Between Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2014, 260, 650-658.	4.2	77
45	Chemopreventive strategies in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 45-54.	17.8	247
46	microRNA: A Promising Diagnostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1099-1107.	2.3	35
47	TGF- β 2 signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. <i>Journal of Gastroenterology</i> , 2014, 49, 971-981.	5.1	23
48	Virus induced inflammation and cancer development. <i>Cancer Letters</i> , 2014, 345, 174-181.	7.2	74
49	Human Viral Oncogenesis: A Cancer Hallmarks Analysis. <i>Cell Host and Microbe</i> , 2014, 15, 266-282.	11.0	531
51	The immune contexture of primary and metastatic human tumours. <i>Current Opinion in Immunology</i> , 2014, 27, 8-15.	5.5	137
52	Identification of genomic alterations in oesophageal squamous cell cancer. <i>Nature</i> , 2014, 509, 91-95.	27.8	903
53	Hepatocellular Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 289-311.	1.5	58
54	The role of Kupffer cells in hepatitis B and hepatitis C virus infections. <i>Journal of Hepatology</i> , 2014, 61, 660-671.	3.7	139
55	Interleukin-6 (IL-6) and IL-17 Synergistically Promote Viral Persistence by Inhibiting Cellular Apoptosis and Cytotoxic T Cell Function. <i>Journal of Virology</i> , 2014, 88, 8479-8489.	3.4	120
56	Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. <i>Oncogene</i> , 2014, 33, 5133-5138.	5.9	42
57	LC-MS Profiling of N-Glycans Derived from Human Serum Samples for Biomarker Discovery in Hepatocellular Carcinoma. <i>Journal of Proteome Research</i> , 2014, 13, 4859-4868.	3.7	46

#	ARTICLE	IF	CITATIONS
58	The pan-cancer analysis of gene expression patterns in the context of inflammation. <i>Molecular BioSystems</i> , 2014, 10, 2270.	2.9	10
59	Antiviral activity of extracts from <i>Morinda citrifolia</i> leaves and chlorophyll catabolites, pheophorbide a and pyropheophorbide a, against hepatitis C virus. <i>Microbiology and Immunology</i> , 2014, 58, 188-194.	1.4	57
60	Non-classical MHC-I human leukocyte antigen (HLA-G) in hepatotropic viral infections and in hepatocellular carcinoma. <i>Human Immunology</i> , 2014, 75, 1225-1231.	2.4	22
61	Viruses and Human Cancers: a Long Road of Discovery of Molecular Paradigms. <i>Clinical Microbiology Reviews</i> , 2014, 27, 463-481.	13.6	169
62	Mobile elements and viral integrations prompt considerations for bacterial DNA integration as a novel carcinogen. <i>Cancer Letters</i> , 2014, 352, 137-144.	7.2	15
64	Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance. <i>Gastroenterology</i> , 2014, 147, 765-783.e4.	1.3	587
65	Overexpression of the Transcription Factor MEF2D in Hepatocellular Carcinoma Sustains Malignant Character by Suppressing G2/M Transition Genes. <i>Cancer Research</i> , 2014, 74, 1452-1462.	0.9	77
66	Dynamic imbalance between cancer cell subpopulations induced by Transforming Growth Factor Beta (TGF- β^2) is associated with a DNA methylome switch. <i>BMC Genomics</i> , 2014, 15, 435.	2.8	27
67	Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis. <i>Virology Journal</i> , 2014, 11, 117.	3.4	26
68	Association of the gene polymorphisms in sodium taurocholate cotransporting polypeptide with the outcomes of hepatitis B infection in Chinese Han population. <i>Infection, Genetics and Evolution</i> , 2014, 27, 77-82.	2.3	20
69	Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus. <i>Tumor Biology</i> , 2014, 35, 9023-9026.	1.8	3
70	Genetic variability of hepatitis B and C viruses in Brazilian patients with and without hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2014, 86, 217-223.	5.0	9
71	Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , 2014, 26, 78-88.	9.6	149
72	Multipotent mesenchymal stromal cells in liver cancer: Implications for tumor biology and therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 439-445.	7.4	10
73	Anti-hepatitis C virus compounds obtained from <i>Glycyrrhiza uralensis</i> and other <i>Glycyrrhiza</i> species. <i>Microbiology and Immunology</i> , 2014, 58, 180-187.	1.4	117
74	Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. <i>Gene</i> , 2014, 543, 101-107.	2.2	53
75	Modeling the effects of covalently closed circular DNA and dendritic cells in chronic HBV infection. <i>Journal of Theoretical Biology</i> , 2014, 357, 1-9.	1.7	12
76	Emerging histopathological prognostic biomarkers in hepatocellular carcinomas. <i>Personalized Medicine Universe</i> , 2014, 3, 15-21.	0.3	1

#	ARTICLE	IF	CITATIONS
77	Comparison of Characteristics and Transarterial Chemoembolization Outcomes in Patients with Unresectable Hepatocellular Carcinoma and Different Viral Etiologies. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 371-378.	0.5	10
78	Hypoxia-inducible factor 1 and its role in viral carcinogenesis. <i>Virology</i> , 2014, 456-457, 370-383.	2.4	63
79	IFI16 mis-localization can be a contributing factor to hepatocellular carcinoma progression. <i>Medical Hypotheses</i> , 2014, 82, 398-400.	1.5	7
80	Molecular mechanisms of hepatic apoptosis. <i>Cell Death and Disease</i> , 2014, 5, e996-e996.	6.3	241
81	Molecular mechanisms of liver injury: Apoptosis or necrosis. <i>Experimental and Toxicologic Pathology</i> , 2014, 66, 351-356.	2.1	63
82	High expression of beta2-glycoprotein I is associated significantly with the earliest stages of hepatitis B virus infection. <i>Journal of Medical Virology</i> , 2014, 86, 1296-1306.	5.0	5
83	Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer. <i>Human Immunology</i> , 2014, 75, 508-513.	2.4	8
85	Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. <i>British Journal of Cancer</i> , 2014, 110, 733-740.	6.4	18
86	Modulation of hepatitis B surface antigen secretion by annexin II expressed in hepatitis B virus-producing hepatoma cells. <i>Molecular Medicine Reports</i> , 2014, 10, 3113-3117.	2.4	4
87	Association Between XPD Lys751Gln and Asp312Asn Polymorphisms and Hepatocellular Carcinoma Risk. <i>Medicine (United States)</i> , 2014, 93, e330.	1.0	16
88	Preserved Function of Circulating Invariant Natural Killer T Cells in Patients With Chronic Hepatitis B Virus Infection. <i>Medicine (United States)</i> , 2015, 94, e961.	1.0	6
89	CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition. <i>Scientific Reports</i> , 2015, 5, 17006.	3.3	30
90	Stabilization of SIRT7 deacetylase by viral oncoprotein HBx leads to inhibition of growth restrictive RPS7 gene and facilitates cellular transformation. <i>Scientific Reports</i> , 2015, 5, 14806.	3.3	17
92	TIPE2 inhibits TNF- α -induced hepatocellular carcinoma cell metastasis via Erk1/2 downregulation and NF- κ B activation. <i>International Journal of Oncology</i> , 2015, 46, 254-264.	3.3	55
93	Reply. <i>Hepatology</i> , 2015, 62, 319-320.	7.3	1
94	Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. <i>Molecular Medicine Reports</i> , 2015, 11, 203-211.	2.4	26
95	Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 431-436.	1.3	19
96	Issue in statistical strategy in case-control study. <i>Hepatology</i> , 2015, 62, 320-320.	7.3	0

#	ARTICLE	IF	CITATIONS
97	Reply. <i>Hepatology</i> , 2015, 62, 320-321.	7.3	0
98	HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 33791-33804.	1.8	84
99	Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2839.	4.3	4
100	Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	19
101	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. <i>Oncotarget</i> , 2015, 6, 3211-3224.	1.8	145
102	Hepatitis B virus therapy: What's the future holding for us?. <i>World Journal of Gastroenterology</i> , 2015, 21, 12558.	3.3	34
103	Relationship between HLA-DP gene polymorphisms and the risk of hepatocellular carcinoma: a meta-analysis. <i>Genetics and Molecular Research</i> , 2015, 14, 15553-15563.	0.2	13
104	Inflammation, cytokines, the IL-17/IL-6/STAT3/NF- κ B axis, and tumorigenesis. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2941.	4.3	31
105	Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?. <i>Diagnostic and Interventional Radiology</i> , 2015, 21, 78-84.	1.5	16
106	Rapid and quantitative detection of hepatitis B virus. <i>World Journal of Gastroenterology</i> , 2015, 21, 11954.	3.3	38
107	Upregulation of endoplasmic reticulum stress and reactive oxygen species by naturally occurring mutations in hepatitis B virus core antigen. <i>Journal of General Virology</i> , 2015, 96, 1850-1854.	2.9	25
108	LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. <i>Proteomics</i> , 2015, 15, 2369-2381.	2.2	66
109	HBx induces the proliferation of hepatocellular carcinoma cells via AP1 over-expressed as a result of ER stress. <i>Biochemical Journal</i> , 2015, 466, 115-121.	3.7	26
111	The Emerging Role of Nuclear Viral DNA Sensors. <i>Journal of Biological Chemistry</i> , 2015, 290, 26412-26421.	3.4	66
112	Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis. <i>Cancer Prevention Research</i> , 2015, 8, 693-701.	1.5	23
113	microRNAs and Hepatitis B. <i>Advances in Experimental Medicine and Biology</i> , 2015, 888, 389-399.	1.6	9
114	Neuropilin-2 induced by transforming growth factor- β 2 augments migration of hepatocellular carcinoma cells. <i>BMC Cancer</i> , 2015, 15, 909.	2.6	30
115	Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs. <i>MBio</i> , 2015, 6, e01500-15.	4.1	39

#	ARTICLE	IF	CITATIONS
116	Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2015, 46, 2546-2554.	3.3	11
117	Impact of <i>Helicobacter pylori</i> on the growth of hepatic orthotopic graft tumors in mice. <i>International Journal of Oncology</i> , 2015, 47, 1416-1428.	3.3	2
118	Full-length single-cell RNA-seq applied to a viral human cancer: applications to HPV expression and splicing analysis in HeLa S3 cells. <i>GigaScience</i> , 2015, 4, 51.	6.4	51
119	Changes in microRNA expression during disease progression in patients with chronic viral hepatitis. <i>Liver International</i> , 2015, 35, 1324-1333.	3.9	12
120	An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. <i>International Immunopharmacology</i> , 2015, 24, 335-345.	3.8	73
121	MICA SNPs and the NKG2D system in virus-induced HCC. <i>Journal of Gastroenterology</i> , 2015, 50, 261-272.	5.1	41
122	Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma. <i>Journal of Clinical Virology</i> , 2015, 64, 64-71.	3.1	18
123	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015, 62, 956-967.	3.7	398
124	Peptide Network for Detection of Tissue-Remodeling Enzyme in the Prognosis of Hepatocellular Carcinoma. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 4401-4405.	8.0	8
125	Rational Design of Selenadiazole Derivatives to Antagonize Hyperglycemia-Induced Drug Resistance in Cancer Cells. <i>Chemistry - an Asian Journal</i> , 2015, 10, 642-652.	3.3	34
126	Inhibition of Hepatitis B Virus Gene Expression and Replication by Hepatocyte Nuclear Factor 6. <i>Journal of Virology</i> , 2015, 89, 4345-4355.	3.4	30
127	Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. <i>British Journal of Cancer</i> , 2015, 112, 1283-1290.	6.4	51
128	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 127-135.	2.8	51
129	Early inhibition of hepatocyte innate responses by hepatitis B virus. <i>Journal of Hepatology</i> , 2015, 63, 1314-1322.	3.7	114
130	Altered microRNA expression profile in hepatitis B virus-related hepatocellular carcinoma. <i>Gene</i> , 2015, 573, 278-284.	2.2	11
131	Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3513-3524.	2.3	36
132	Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. <i>Clinical Microbiology and Infection</i> , 2015, 21, 969-974.	6.0	29
133	Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. <i>Carcinogenesis</i> , 2015, 36, 1136-1143.	2.8	107

#	ARTICLE	IF	CITATIONS
134	Increased ARPP-19 Expression Is Associated with Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2015, 16, 178-192.	4.1	17
135	Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. <i>Oncology Letters</i> , 2015, 9, 1201-1206.	1.8	18
136	Oncogenic Viruses and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 341-360.	2.1	16
137	Expression and characterization of myristoylated preS1-conjugated nanocages for targeted cell delivery. <i>Protein Expression and Purification</i> , 2015, 110, 52-56.	1.3	4
138	Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors. <i>Clinical Epigenetics</i> , 2015, 7, 15.	4.1	24
139	TREM-1, an Inflammatory Modulator, is Expressed in Hepatocellular Carcinoma Cells and Significantly Promotes Tumor Progression. <i>Annals of Surgical Oncology</i> , 2015, 22, 3121-3129.	1.5	50
140	Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. <i>Pharmacological Research</i> , 2015, 97, 84-103.	7.1	198
141	The Role of L-Tryptophan Kynurenine Pathway Metabolism in Various Infectious Diseases: Focus on Indoleamine 2,3-Dioxygenase 1. <i>Molecular and Integrative Toxicology</i> , 2015, , 95-120.	0.5	1
142	Segmental Transarterial Embolization in a Translational Rat Model of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1229-1237.	0.5	32
143	Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6607-6612.	7.1	78
144	A Comparison of the Surgical Outcomes Among Patients With HBV-positive, HCV-positive, and Non-B Non-C Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, 513-520.	4.2	130
145	Identification of characteristic TRB V usage in HBV-associated HCC by using differential expression profiling analysis. <i>OncImmunology</i> , 2015, 4, e1021537.	4.6	41
146	The evolving epidemiology of hepatocellular carcinoma: a global perspective. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 765-779.	3.0	305
147	Oncogenic potential of hepatitis B virus encoded proteins. <i>Current Opinion in Virology</i> , 2015, 14, 109-115.	5.4	21
148	Degradation of miR-21 induces apoptosis and inhibits cell proliferation in human hepatocellular carcinoma. <i>Cancer Gene Therapy</i> , 2015, 22, 530-535.	4.6	43
149	Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. <i>Nature Immunology</i> , 2015, 16, 1235-1244.	14.5	278
150	Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C. <i>Scientific Reports</i> , 2015, 5, 7675.	3.3	122
151	Hepatitis B virus X promotes hepatocellular carcinoma development via nuclear protein 1 pathway. <i>Biochemical and Biophysical Research Communications</i> , 2015, 466, 676-681.	2.1	17

#	ARTICLE	IF	CITATIONS
153	The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1125-1132.	1.5	32
154	Quick Serological Detection of a Cancer Biomarker with an Agglutinated Supramolecular Glycophage. <i>Analytical Chemistry</i> , 2015, 87, 9078-9083.	6.5	22
155	Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes. <i>Journal of Virology</i> , 2015, 89, 11549-11556.	3.4	37
156	European Code against Cancer 4th Edition: Infections and Cancer. <i>Cancer Epidemiology</i> , 2015, 39, S120-S138.	1.9	34
157	Hippo Pathway Regulation of Gastrointestinal Tissues. <i>Annual Review of Physiology</i> , 2015, 77, 201-227.	13.1	103
158	The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. <i>Journal of Pathology</i> , 2015, 235, 355-367.	4.5	116
159	Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. <i>Gut</i> , 2015, 64, 820-829.	12.1	127
160	Genomic analysis of fibrolamellar hepatocellular carcinoma. <i>Human Molecular Genetics</i> , 2015, 24, 50-63.	2.9	90
161	Systematic tracking of disrupted modules identifies significant genes and pathways in hepatocellular carcinoma. <i>Oncology Letters</i> , 2016, 12, 3285-3295.	1.8	8
162	The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair. <i>Genes</i> , 2016, 7, 28.	2.4	65
163	Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. <i>Journal of Clinical Trials</i> , 2016, 06, .	0.1	23
164	Combined acoustic radiation force impulse, aminotransferase to platelet ratio index and Forns index assessment for hepatic fibrosis grading in hepatitis B. <i>World Journal of Hepatology</i> , 2016, 8, 616.	2.0	8
165	Fish, Fish Oil, and Liver Cancer. , 2016, , 249-262.		0
166	Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 173.	2.0	28
167	Ion Channels and Oxidative Stress as a Potential Link for the Diagnosis or Treatment of Liver Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-17.	4.0	55
168	Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-10.	4.0	122
169	Identifying significant pathways of hepatitis B virus-related hepatocellular carcinoma based on crosstalk and network pathways. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.2	2
170	Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 81255-81267.	1.8	87

#	ARTICLE	IF	CITATIONS
171	The Wnt pathway: a key network in cell signalling dysregulated by viruses. <i>Reviews in Medical Virology</i> , 2016, 26, 340-355.	8.3	39
172	<scp>HB</scp>x triggers either cellular senescence or cell proliferation depending on cellular phenotype. <i>Journal of Viral Hepatitis</i> , 2016, 23, 130-138.	2.0	15
173	EHHM, a novel phenolic natural product from <i>Livistona chinensis</i> , induces autophagy-related apoptosis in hepatocellular carcinoma cells. <i>Oncology Letters</i> , 2016, 12, 3739-3748.	1.8	13
174	Liver epithelial cells inhibit proliferation and invasiveness of hepatoma cells. <i>Oncology Reports</i> , 2016, 35, 1622-1628.	2.6	1
175	Hepatitis C virus core protein regulates OCT4 expression and promotes cell cycle progression in hepatocellular carcinoma. <i>Oncology Reports</i> , 2016, 36, 582-588.	2.6	8
176	A Function Variant at miR-501 Alters Susceptibility to Hepatocellular Carcinoma in a Chinese Han Population. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 2500-2508.	1.6	29
177	Investigating genetic characteristics of hepatitis B virus-associated and -non-associated hepatocellular carcinoma. <i>Genetical Research</i> , 2016, 98, e14.	0.9	0
178	In-Depth Proteomic Quantification of Cell Secretome in Serum-Containing Conditioned Medium. <i>Analytical Chemistry</i> , 2016, 88, 4971-4978.	6.5	35
179	Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis. <i>Nucleic Acids Research</i> , 2016, 44, 5529-5539.	14.5	35
180	Protein-protein interactions among signaling pathways may become new therapeutic targets in liver cancer (Review). <i>Oncology Reports</i> , 2016, 35, 625-638.	2.6	8
181	Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2016, 79, 208-214.	5.6	9
182	Polymorphisms in sodium taurocholate cotransporting polypeptide are not associated with hepatitis B virus clearance in Chinese Tibetans and Uygurs. <i>Infection, Genetics and Evolution</i> , 2016, 41, 128-134.	2.3	13
183	Hepatitis B virus inhibits insulin receptor signaling and impairs liver regeneration via intracellular retention of the insulin receptor. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 4121-4140.	5.4	15
184	Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis. <i>Clinical and Translational Immunology</i> , 2016, 5, e101.	3.8	12
185	A cerium-based metal-organic tetrahedron for fluorescent recognition of 5-HIAA and its application in urine test. <i>Inorganic Chemistry Communication</i> , 2016, 73, 129-133.	3.9	5
186	IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo. <i>Tumor Biology</i> , 2016, 37, 14677-14686.	1.8	7
187	Identification of hub genes and pathways associated with hepatocellular carcinoma based on network strategy. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 2109-2119.	1.8	14
188	Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?. <i>Personalized Medicine</i> , 2016, 13, 455-467.	1.5	11

#	ARTICLE	IF	CITATIONS
189	High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC. <i>Onc Immunology</i> , 2016, 5, e1219010.	4.6	88
190	Are virus-induced cancers more sensitive to checkpoint inhibitors?. <i>Future Oncology</i> , 2016, 12, 2665-2668.	2.4	14
191	Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. <i>Clinical Microbiology and Infection</i> , 2016, 22, 853-861.	6.0	125
192	Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 74.	17.0	146
193	Impact of non-neoplastic vs intratumoural hepatitis B viral DNA and replication on hepatocellular carcinoma recurrence. <i>British Journal of Cancer</i> , 2016, 115, 841-847.	6.4	12
194	Potential effects of \pm -mangostin in the prevention and treatment of hepatocellular carcinoma. <i>Journal of Functional Foods</i> , 2016, 26, 309-318.	3.4	13
195	Genomic Signatures of Risk Factors and Molecular Identification of HCC Subtypes. , 2016, , 113-119.		0
196	Hepatocellular Carcinoma and Hepatitis C Virus. , 2016, , 109-136.		1
197	A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. <i>BMC Infectious Diseases</i> , 2016, 16, 647.	2.9	35
198	Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size. <i>Journal of Immunotherapy</i> , 2016, 39, 36-44.	2.4	13
199	The epithelial-mesenchymal transition (EMT) is regulated by oncoviruses in cancer. <i>FASEB Journal</i> , 2016, 30, 3001-3010.	0.5	58
200	Comparison of genome-scale DNA methylation profiles in hepatocellular carcinoma by viral status. <i>Epigenetics</i> , 2016, 11, 464-474.	2.7	15
201	ShRNA-mediated silencing of the Ndc80 gene suppress cell proliferation and affected hepatitis B virus-related hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 297-303.	1.5	12
202	PRKAA/AMPK restricts HBV replication through promotion of autophagic degradation. <i>Autophagy</i> , 2016, 12, 1507-1520.	9.1	58
203	Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV. <i>Gut</i> , 2016, 65, 502-511.	12.1	28
204	Critical role for the long non-coding RNA AFAP1-AS1 in the proliferation and metastasis of hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 9699-9707.	1.8	62
205	Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus-associated hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2016, 13, 1077-1082.	2.4	8
206	Pathobiology of Hepatitis B Virus-Induced Carcinogenesis. <i>Molecular and Translational Medicine</i> , 2016, , 95-121.	0.4	2

#	ARTICLE	IF	CITATIONS
207	Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma. <i>Phytotherapy Research</i> , 2016, 30, 863-877.	5.8	26
208	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	2.2	160
209	Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 574-582.	1.5	13
210	Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 998-1008.	1.3	178
211	Metabolic reprogramming: a hallmark of viral oncogenesis. <i>Oncogene</i> , 2016, 35, 4155-4164.	5.9	44
212	Ultrasensitive, Multiplex Raman Frequency Shift Immunoassay of Liver Cancer Biomarkers in Physiological Media. <i>ACS Nano</i> , 2016, 10, 871-879.	14.6	91
213	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. <i>Translational Research</i> , 2016, 168, 122-133.	5.0	19
214	The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. <i>Cell Death and Differentiation</i> , 2016, 23, 576-582.	11.2	52
215	Serum hepatitis B surface antigen correlates with tissue covalently closed circular DNA in patients with hepatitis B-associated hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2016, 88, 244-251.	5.0	13
216	The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 379, 262-267.	7.2	14
217	Heterogeneity of liver cancer and personalized therapy. <i>Cancer Letters</i> , 2016, 379, 191-197.	7.2	202
218	Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4. <i>Pathology Research and Practice</i> , 2017, 213, 245-249.	2.3	30
219	COMMD7 promotes hepatocellular carcinoma through regulating CXCL10. <i>Biomedicine and Pharmacotherapy</i> , 2017, 88, 653-657.	5.6	19
220	MicroRNA profile analysis in the liver fibrotic tissues of chronic hepatitis B patients. <i>Journal of Digestive Diseases</i> , 2017, 18, 115-124.	1.5	13
221	The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 986-992.	3.6	50
222	Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence. <i>Pathology Research and Practice</i> , 2017, 213, 316-321.	2.3	64
223	Distinct patterns and prognostic values of tumor-infiltrating macrophages in hepatocellular carcinoma and gastric cancer. <i>Journal of Translational Medicine</i> , 2017, 15, 37.	4.4	41
224	In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	117

#	ARTICLE	IF	CITATIONS
225	Identifying the optimal gene and gene set in hepatocellular carcinoma based on differential expression and differential co-expression algorithm. <i>Oncology Reports</i> , 2017, 37, 1066-1074.	2.6	6
226	SERS-based ultrasensitive sensing platform: An insight into design and practical applications. <i>Coordination Chemistry Reviews</i> , 2017, 337, 1-33.	18.8	97
227	Anti-hepatoma activities of ethyl acetate extract from <i>Ampelopsis sinica</i> root. <i>Oncology Reports</i> , 2017, 37, 2227-2236.	2.6	6
228	Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1043-1050.e2.	0.5	18
229	Antiviral Therapy Reduces Risk of Haemorrhagic Stroke in Patients with HCV Infection: A Nationwide Cohort Study. <i>Antiviral Therapy</i> , 2018, 23, 43-52.	1.0	4
230	The risk of HCV infection among health-care workers and its association with extrahepatic manifestations. <i>Molecular Medicine Reports</i> , 2017, 15, 3336-3339.	2.4	14
231	Hepatitis delta and HIV infection. <i>Aids</i> , 2017, 31, 875-884.	2.2	35
232	Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells. <i>Cancer Letters</i> , 2017, 400, 149-160.	7.2	35
233	Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans. <i>Trends in Microbiology</i> , 2017, 25, 833-850.	7.7	65
234	Therapeutic Vaccine of Gastric Cancer. , 2017, , 131-147.		0
235	Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2017, 141, 977-985.	5.1	71
237	CAMK2 β in intestinal epithelial cells modulates colitis-associated colorectal carcinogenesis via enhancing STAT3 activation. <i>Oncogene</i> , 2017, 36, 4060-4071.	5.9	31
238	Implications of oxidative stress on viral pathogenesis. <i>Archives of Virology</i> , 2017, 162, 907-917.	2.1	153
239	Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma. <i>Journal of Biological Chemistry</i> , 2017, 292, 21676-21689.	3.4	34
240	FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4 β -GSK3 β -Nrf2 Signaling. <i>Cancer Research</i> , 2017, 77, 6215-6225.	0.9	65
241	Hepatitis C Virus-Associated Cancers. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1018, 129-146.	1.6	23
242	Hepatitis B Virus Core Antigen Stimulates IL-6 Expression via p38, ERK and NF- κ B Pathways in Hepatocytes. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 91-100.	1.6	25
243	Cape gooseberry (<i>Physalis peruviana</i>) juice as a modulator agent for hepatocellular carcinoma-linked apoptosis and cell cycle arrest. <i>Biomedicine and Pharmacotherapy</i> , 2017, 94, 1129-1137.	5.6	21

#	ARTICLE	IF	CITATIONS
244	Viral hepatitis and liver cancer. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160274.	4.0	265
245	p16 Methylation was associated with the development, age, hepatic viruses infection of hepatocellular carcinoma, and p16 expression had a poor survival. <i>Medicine (United States)</i> , 2017, 96, e8106.	1.0	21
246	Up-regulation of BRCA1-associated RING Domain 1 Promotes Hepatocellular Carcinoma Progression by Targeting Akt Signaling. <i>Scientific Reports</i> , 2017, 7, 7649.	3.3	12
247	Hepatitis C virus-induced tumor-initiating cancer stem-like cells activate stromal fibroblasts in a xenograft tumor model. <i>Hepatology</i> , 2017, 66, 1766-1778.	7.3	19
248	How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?. <i>Journal of Hepatology</i> , 2017, 67, 1281-1297.	3.7	132
249	Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. <i>Medicine (United States)</i> , 2017, 96, e7438.	1.0	9
250	Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma. <i>Gene</i> , 2017, 629, 29-34.	2.2	20
251	Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 2066-2077.	7.3	150
253	Infectious Agents Associated Cancers: Epidemiology and Molecular Biology. <i>Advances in Experimental Medicine and Biology</i> , 2017, .	1.6	4
254	Extended chain conformation of Î ² -glucan and its effect on antitumor activity. <i>Journal of Materials Chemistry B</i> , 2017, 5, 5623-5631.	5.8	43
255	Circulating microRNAs as potential biomarkers of HBV infection persistence. <i>Infection, Genetics and Evolution</i> , 2017, 54, 152-157.	2.3	5
256	miR-363-5p as potential prognostic marker for hepatocellular carcinoma indicated by weighted co-expression network analysis of miRNAs and mRNA. <i>BMC Gastroenterology</i> , 2017, 17, 81.	2.0	18
257	Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2017, 12, 27.	2.6	40
258	Bigger Is Better: Refinement of an Animal Model of Hepatocellular Carcinoma and Transfemoral Arterial Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1051-1052.	0.5	0
259	Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 209-215.	1.5	17
260	New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 35-44.	1.8	19
261	Expression of a hepatitis B virus pre-S2 deletion mutant in the liver results in hepatomegaly and hepatocellular carcinoma in mice. <i>Journal of Pathology</i> , 2017, 241, 463-474.	4.5	38
262	Redox proteomics screening cellular factors associated with oxidative stress in hepatocarcinogenesis. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600089.	1.6	10

#	ARTICLE	IF	CITATIONS
263	Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. <i>Cytokine</i> , 2017, 90, 54-59.	3.2	17
264	CAMK2 β antagonizes mTORC1 activation during hepatocarcinogenesis. <i>Oncogene</i> , 2017, 36, 2446-2456.	5.9	16
265	Hepatitis C virus core protein increases Snail expression and induces epithelial-mesenchymal transition through the signal transducer and activator of transcription3 pathway in hepatoma cells. <i>Hepatology Research</i> , 2017, 47, 574-583.	3.4	14
266	Analysis of expression profile data identifies key genes and pathways in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 2625-2630.	1.8	6
267	Matrix Metalloproteinases (MMPs) as Cancer Therapeutic Targets. , 2017, , 157-185.		0
268	Comparative Analysis for Glycopatterns and Complex-Type N-Glycans of Glycoprotein in Sera from Chronic Hepatitis B- and C-Infected Patients. <i>Frontiers in Physiology</i> , 2017, 8, 596.	2.8	15
269	Oxidative Stress as a Mechanism for Hepatocellular Carcinoma. , 2017, , 279-287.		4
270	Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model. <i>BMC Genomics</i> , 2017, 18, 641.	2.8	21
271	Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2550.	4.1	73
272	Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs. <i>Molecules</i> , 2017, 22, 883.	3.8	21
273	LncRNA-AF113014 promotes the expression of Egr2 by interaction with miR-20a to inhibit proliferation of hepatocellular carcinoma cells. <i>PLoS ONE</i> , 2017, 12, e0177843.	2.5	20
274	Low-Grade Dysplastic Nodules Revealed as the Tipping Point during Multistep Hepatocarcinogenesis by Dynamic Network Biomarkers. <i>Genes</i> , 2017, 8, 268.	2.4	10
275	Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. <i>Mediators of Inflammation</i> , 2017, 2017, 1-12.	3.0	37
276	Near-infrared fluorescence imaging and photodynamic therapy with indocyanine green lactosome has antineoplastic effects for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0183527.	2.5	26
277	Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker. <i>BMC Cancer</i> , 2017, 17, 644.	2.6	14
278	A pilot systematic genomic comparison of recurrence risks of hepatitis B virus-associated hepatocellular carcinoma with low- and high-degree liver fibrosis. <i>BMC Medicine</i> , 2017, 15, 214.	5.5	64
279	Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1 α under hypoxia. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 481-486.	2.1	24
280	MCEE: a data preprocessing approach for metabolic confounding effect elimination. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 2689-2699.	3.7	7

#	ARTICLE	IF	CITATIONS
281	In Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma. Molecular and Cellular Proteomics, 2018, 17, 1067-1083.	3.8	27
282	Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. Cancer Science, 2018, 109, 600-610.	3.9	24
283	Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels. Annals of Surgery, 2018, 268, 943-954.	4.2	97
284	Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21 ^{Waf1/Cip1} and p19 ^{INK4d} upregulation in hepatocellular carcinoma. Cell Proliferation, 2018, 51, e12447.	5.3	63
285	The role of molecular enrichment on future therapies in hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 237-247.	3.7	95
286	New design of probe and central-homo primer pairs to improve TaqMan [®] PCR accuracy for HBV detection. Journal of Virological Methods, 2018, 254, 25-30.	2.1	6
287	Tumours and Tumour-like Lesions of the Liver. , 2018, , 780-879.		18
288	Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model. Translational Oncology, 2018, 11, 250-258.	3.7	57
289	Association of genetic variants in the interleukin-18 gene promoter with risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus infection. IUBMB Life, 2018, 70, 165-174.	3.4	9
290	Viruses as key modulators of the TGF β 2 pathway; a double-edged sword involved in cancer. Reviews in Medical Virology, 2018, 28, e1967.	8.3	42
291	Tropism of liver epithelial cells toward hepatocellular carcinoma in vitro and in vivo with altering gene expression of cancer stem cells. American Journal of Surgery, 2018, 215, 735-743.	1.8	0
292	Long non-coding RNA CCAL promotes hepatocellular carcinoma progression by regulating AP-2 β and Wnt/ β -catenin pathway. International Journal of Biological Macromolecules, 2018, 109, 424-434.	7.5	24
293	Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system. Hepatology, 2018, 68, 141-154.	7.3	84
295	Genomics Studies in Hepatocellular Carcinoma via Next-Generation Sequencing. Molecular Pathology Library, 2018, , 49-68.	0.1	1
296	p19Arf inhibits aggressive progression of H-ras-driven hepatocellular carcinoma. Carcinogenesis, 2018, 39, 318-326.	2.8	2
297	Expression of hepatic Wnt5a and its clinicopathological features in patients with hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2018, 17, 227-232.	1.3	14
298	The role of ROS-induced autophagy in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 306-312.	1.5	44
299	PDK1-WNK1 signaling is affected by HBx and involved in the viability and metastasis of hepatic cells. Oncology Letters, 2018, 15, 5940-5946.	1.8	9

#	ARTICLE	IF	CITATIONS
300	MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. <i>Gene</i> , 2018, 659, 168-174.	2.2	28
301	An antibody-free assay for simultaneous capture and detection of glycoproteins by surface enhanced Raman spectroscopy. <i>Physical Chemistry Chemical Physics</i> , 2018, 20, 8881-8886.	2.8	26
302	Precision diagnosis and treatment of liver cancer in China. <i>Cancer Letters</i> , 2018, 412, 283-288.	7.2	226
303	HBxAg suppresses cell apoptosis and promotes the secretion of placental hormones in human placental trophoblasts via activation of the EGFR/Akt pathway. <i>Cell Biology International</i> , 2018, 42, 237-247.	3.0	7
304	The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. <i>International Journal of Cancer</i> , 2018, 142, 81-91.	5.1	47
305	HCV immune evasion and regulatory T cell activation: cause or consequence?. <i>Cellular and Molecular Immunology</i> , 2018, 15, 536-538.	10.5	4
306	COMMD7 activates CXCL10 production by regulating NF- κ B and the production of reactive oxygen species. <i>Molecular Medicine Reports</i> , 2018, 17, 6784-6788.	2.4	8
307	Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 429-439.	1.5	16
308	MicroRNA-130a inhibits the proliferation, migration and invasive ability of hepatocellular carcinoma cells by downregulating Rho-kinase 2. <i>Molecular Medicine Reports</i> , 2018, 18, 3077-3084.	2.4	10
309	Pathogenesis of Hepatitis B Virus Associated Chronic Liver Disease. , 2018, , .		2
310	CAR-T cells shed light on the treatments of fatal liver diseases. <i>Biotarget</i> , 0, 2, 6-6.	0.5	1
311	Recent Advances in HBV Reactivation Research. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	29
312	TLR3 Activation of Hepatic Stellate Cell Line Suppresses HBV Replication in HepG2 Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2921.	4.8	6
313	Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. <i>Cancers</i> , 2018, 10, 481.	3.7	135
314	Ultrasensitive Detection of Serum MicroRNA Using Branched DNA-Based SERS Platform Combining Simultaneous Detection of α -Fetoprotein for Early Diagnosis of Liver Cancer. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 34869-34877.	8.0	60
315	Knockdown of FOXK1 suppresses liver cancer cell viability by inhibiting glycolysis. <i>Life Sciences</i> , 2018, 213, 66-73.	4.3	27
316	Do polymorphisms in protein kinase catalytic subunit alpha-1 gene associated with cancer susceptibility? a meta-analysis and systematic review. <i>BMC Medical Genetics</i> , 2018, 19, 189.	2.1	7
317	Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma. <i>Viruses</i> , 2018, 10, 591.	3.3	30

#	ARTICLE	IF	CITATIONS
318	The impact of antiviral therapy on hepatocellular carcinoma epidemiology. <i>Hepatic Oncology</i> , 2018, 5, HEP03.	4.2	14
319	Hepatitis B virus downregulates vitamin D receptor levels in hepatoma cell lines, thereby preventing vitamin D-dependent inhibition of viral transcription and production. <i>Molecular Medicine</i> , 2018, 24, 53.	4.4	48
320	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , 2018, 10, 595-602.	2.0	12
321	Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis. <i>PLoS ONE</i> , 2018, 13, e0204031.	2.5	14
322	Hepatitis B Virus Infection Dampens CtIP Expression in Hepatoma Cell. <i>Journal of Cancer</i> , 2018, 9, 1182-1187.	2.5	3
323	Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. <i>PLoS ONE</i> , 2018, 13, e0202650.	2.5	15
324	Cytotoxic Effect of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) on Liver Cancer Cell Integrated with Hepatitis B Genome, Hep3B. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-13.	1.2	24
325	Chimeric antigen receptor-engineered T-cell therapy for liver cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 301-309.	1.3	59
326	Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/ β -catenin signaling activation (Review). <i>International Journal of Molecular Medicine</i> , 2018, 42, 713-725.	4.0	125
327	Overactivated neddylation pathway in human hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 3363-3372.	2.8	35
328	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 872-881.	3.4	16
329	T cell receptor repertoire profiling predicts the prognosis of HBV-associated hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 3755-3762.	2.8	18
330	Hepatic Tumors. , 2018, , 383-394.		0
331	Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient. <i>Virus Research</i> , 2018, 255, 165-170.	2.2	8
332	Precision Medicine: Update on Diagnosis and Therapeutic Strategies of Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2018, 25, 1999-2008.	2.4	19
333	Dichotomous associations of liver pathology with hepatocellular carcinoma morphology in Middle Africa: the situation in Cameroon. <i>BMC Research Notes</i> , 2018, 11, 451.	1.4	3
334	HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation. <i>International Journal of Cancer</i> , 2018, 143, 3120-3130.	5.1	51
335	Role of nonresolving inflammation in hepatocellular carcinoma development and progression. <i>Npj Precision Oncology</i> , 2018, 2, 6.	5.4	199

#	ARTICLE	IF	CITATIONS
336	Association between serum S100A9 levels and liver necroinflammation in chronic hepatitis B. <i>Journal of Translational Medicine</i> , 2018, 16, 83.	4.4	22
337	Occult hepatitis B infection: a hidden factor of poor response to intervention treatment of hepatocellular carcinoma in chronic hepatitis C patients. <i>Comparative Clinical Pathology</i> , 2018, 27, 1273-1279.	0.7	1
338	Comparison of the methods for profiling N-glycans in hepatocellular carcinoma serum glycomics study. <i>RSC Advances</i> , 2018, 8, 26116-26123.	3.6	2
339	Dietary patterns and primary liver cancer in Chinese adults: a case-control study. <i>Oncotarget</i> , 2018, 9, 27872-27881.	1.8	5
340	MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation. <i>Oncology Letters</i> , 2018, 15, 9126-9132.	1.8	9
341	The Potential Role of TNF- α (rs361525 and rs1800629) in Hepatocellular Carcinoma: Multivariate Analysis (Meta-Analysis). <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 744-749.	1.3	3
342	Molecular Alterations and Heterogeneity in Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 293-316.	0.4	4
343	The Role of Deubiquitinases in Oncovirus and Host Interactions. <i>Journal of Oncology</i> , 2019, 2019, 1-9.	1.3	11
344	Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 708-714.	1.9	2
345	Steroid receptor coactivator 3 inhibits hepatitis B virus gene expression through activating Akt signaling to prevent HNF4 α nuclear translocation. <i>Cell and Bioscience</i> , 2019, 9, 64.	4.8	5
346	Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas. <i>Genes</i> , 2019, 10, 630.	2.4	38
348	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019, 9, 10529.	3.3	12
349	Noncanonical Role of FBXO6 in Regulating Antiviral Immunity. <i>Journal of Immunology</i> , 2019, 203, 1012-1020.	0.8	15
350	G protein-coupled receptor kinase 2 regulating β 2-adrenergic receptor signaling in M2-polarized macrophages contributes to hepatocellular carcinoma progression. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5499-5513.	2.0	11
351	Genomic modeling of hepatitis B virus integration frequency in the human genome. <i>PLoS ONE</i> , 2019, 14, e0220376.	2.5	34
352	MiR-718 mediates the indirect interaction between lncRNA SEMA3B-AS1 and PTEN to regulate the proliferation of hepatocellular carcinoma cells. <i>Physiological Genomics</i> , 2019, 51, 500-505.	2.3	20
353	Cross-Species Suppression of Hepatoma Cell Growth and Migration by a <i>Schistosoma japonicum</i> MicroRNA. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 400-412.	5.1	19
354	Tumor necrosis factor- α -induced protein 8-like 2 mRNA in peripheral blood mononuclear cells is associated with the disease progression of chronic hepatitis B virus infection. <i>Virology Journal</i> , 2019, 16, 120.	3.4	3

#	ARTICLE	IF	CITATIONS
355	<p>Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine</p>. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 151-166.	3.7	25
356	The MOV10 helicase restricts hepatitis B virus replication by inhibiting viral reverse transcription. Journal of Biological Chemistry, 2019, 294, 19804-19813.	3.4	17
357	New $\hat{\pm}$, $\hat{2}$ -unsaturated bis-enone derivatives: Anticancer activity in human osteogenic sarcoma cells and docking study. Main Group Chemistry, 2019, 18, 315-323.	0.8	0
358	A comprehensive genome-wide profiling comparison between HBV and HCV infected hepatocellular carcinoma. BMC Medical Genomics, 2019, 12, 147.	1.5	21
359	Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma. Frontiers in Oncology, 2019, 9, 1156.	2.8	18
360	A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System. Journal of NeuroImmune Pharmacology, 2019, 14, 578-594.	4.1	5
361	Wasserstein GAN-Based Small-Sample Augmentation for New-Generation Artificial Intelligence: A Case Study of Cancer-Staging Data in Biology. Engineering, 2019, 5, 156-163.	6.7	101
362	Hepatocellular Carcinoma: Etiology and Current and Future Drugs. Journal of Clinical and Experimental Hepatology, 2019, 9, 221-232.	0.9	167
363	Autophagy: Dual Response in the Development of Hepatocellular Carcinoma. Cells, 2019, 8, 91.	4.1	67
364	<p>Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets</p>. Cancer Management and Research, 2019, Volume 11, 3921-3931.	1.9	91
365	Pathological Pattern of Intrahepatic HBV in HCC is Phenocopied by PDX-Derived Mice: a Novel Model for Antiviral Treatment. Translational Oncology, 2019, 12, 1138-1146.	3.7	10
366	Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells, 2019, 8, 604.	4.1	12
367	LncRNA PLAC2 upregulates p53 to induce hepatocellular carcinoma cell apoptosis. Gene, 2019, 712, 143944.	2.2	15
368	Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian Journal of Pharmaceutical Sciences, 2019, 14, 581-594.	9.1	97
369	Hepatitis B virus X protein (HBx) enhances centrosomal P4.1-associated protein (CPAP) expression to promote hepatocarcinogenesis. Journal of Biomedical Science, 2019, 26, 44.	7.0	28
370	There Is Something Fishy About Liver Cancer: Zebrafish Models of Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 347-363.	4.5	35
371	APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut, 2019, 68, 1846-1857.	12.1	59
372	What Have We Learned from Studies of IFN- \hat{b} Variants and Hepatitis C Virus Infection?. Journal of Interferon and Cytokine Research, 2019, 39, 618-626.	1.2	3

#	ARTICLE	IF	CITATIONS
373	Immune checkpoint inhibitors in the treatment of virus-associated cancers. <i>Journal of Hematology and Oncology</i> , 2019, 12, 58.	17.0	43
374	Enrichment in selected genotypes, basal core and precore mutations of hepatitis B virus in patients with hepatocellular carcinoma in Cameroon. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1086-1093.	2.0	10
375	PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 204.	8.6	66
376	Proteoglycans and Immunobiology of Cancer—Therapeutic Implications. <i>Frontiers in Immunology</i> , 2019, 10, 875.	4.8	36
377	Natural killer cells involved in tumour immune escape of hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2019, 73, 10-16.	3.8	16
378	Transcriptome analysis identifies metallothionein as biomarkers to predict recurrence in hepatocellular carcinoma. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e693.	1.2	7
379	Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression. <i>World Journal of Gastroenterology</i> , 2019, 25, 398-410.	3.3	42
380	Compound <i>Phyllanthus urinaria</i> L Inhibits HBV-Related HCC through HBx-SHH Pathway Axis Inactivation. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-15.	1.2	11
381	Establishment of an in vitro reporter system for screening HBx-targeting molecules. <i>Acta Biochimica Et Biophysica Sinica</i> , 2019, 51, 431-440.	2.0	3
382	SNP rs2596542G>A in MICA is associated with risk of hepatocellular carcinoma: a meta-analysis. <i>Bioscience Reports</i> , 2019, 39, .	2.4	12
383	<i>Schistosoma japonicum</i> MiRNA-7-5p Inhibits the Growth and Migration of Hepatoma Cells via Cross-Species Regulation of S-Phase Kinase-Associated Protein 2. <i>Frontiers in Oncology</i> , 2019, 9, 175.	2.8	33
384	Microbiome and Human Malignancies. <i>Current Cancer Research</i> , 2019, , 1-22.	0.2	1
385	Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. <i>Oncogene</i> , 2019, 38, 4804-4819.	5.9	33
386	Elevated serum activity of MBL and ficolin-2 as biomarkers for progression to hepatocellular carcinoma in chronic HCV infection. <i>Virology</i> , 2019, 530, 99-106.	2.4	9
387	The associations between Toll-like receptor 4 gene polymorphisms and hepatitis C virus infection: a systematic review and meta-analysis. <i>Bioscience Reports</i> , 2019, 39, .	2.4	6
388	Paradoxical Roles of Oxidative Stress Response in the Digestive System before and after Carcinogenesis. <i>Cancers</i> , 2019, 11, 213.	3.7	19
389	Association between gene methylation and HBV infection in hepatocellular carcinoma: A meta-analysis. <i>Journal of Cancer</i> , 2019, 10, 6457-6465.	2.5	19
390	Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-20.	7.7	40

#	ARTICLE	IF	CITATIONS
391	Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 716-722.	1.6	13
393	Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. <i>European Journal of Surgical Oncology</i> , 2019, 45, 800-807.	1.0	12
394	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. <i>Gastroenterology</i> , 2019, 156, 400-417.	1.3	35
395	Peroxiredoxin 1, a Novel HBx-Interacting Protein, Interacts with Exosome Component 5 and Negatively Regulates Hepatitis B Virus (HBV) Propagation through Degradation of HBV RNA. <i>Journal of Virology</i> , 2019, 93, .	3.4	30
396	Hypoxia induced β -Catenin to enhance mice hepatocellular carcinoma progression via Wnt signaling. <i>Experimental Cell Research</i> , 2019, 374, 94-103.	2.6	12
397	Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. <i>Journal of Pathology</i> , 2019, 247, 615-628.	4.5	70
398	Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Anatomical Record</i> , 2019, 302, 193-200.	1.4	5
399	DNA methyltransferases in virus-associated cancers. <i>Reviews in Medical Virology</i> , 2019, 29, e2022.	8.3	18
400	Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2019, 269, 692-699.	4.2	53
401	Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type A Receptor 5 Kinases in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 573-586.	7.3	12
402	Molecular and cellular interplay in virus-induced tumors in solid organ recipients. <i>Cellular Immunology</i> , 2019, 343, 103770.	3.0	8
403	Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. <i>Annals of Surgery</i> , 2019, 270, 121-130.	4.2	48
404	HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein. <i>Hepatology</i> , 2020, 71, 1678-1695.	7.3	42
405	Eph receptors: the bridge linking host and virus. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2355-2365.	5.4	31
406	Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 80-95.	4.2	15
407	Circulating exosome-derived bona fide long non-coding RNAs predicting the occurrence and metastasis of hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1311-1318.	3.6	45
408	Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 221, 1677-1687.	4.0	182
409	Advances in therapeutic application of CRISPR-Cas9. <i>Briefings in Functional Genomics</i> , 2020, 19, 164-174.	2.7	9

#	ARTICLE	IF	CITATIONS
410	MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 1-21.	2.0	23
411	Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis. <i>Pathology Research and Practice</i> , 2020, 216, 153099.	2.3	7
412	Serum ammonia is a strong prognostic factor for patients with acute-on-chronic liver failure. <i>Scientific Reports</i> , 2020, 10, 16970.	3.3	18
413	Innovative HBV Animal Models Based on the Entry Receptor NTCP. <i>Viruses</i> , 2020, 12, 828.	3.3	10
414	Virome assembly and annotation in brain tissue based on next-generation sequencing. <i>Cancer Medicine</i> , 2020, 9, 6776-6790.	2.8	8
415	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	5.1	7
416	The Role of Smoothed in Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6863.	4.1	40
417	Antiproliferative effect of the Red Sea cone snail, <i>Conus geographus</i> . <i>Tropical Journal of Pharmaceutical Research</i> , 2020, 19, 577-581.	0.3	3
418	De novo lipogenesis is elicited dramatically in human hepatocellular carcinoma especially in hepatitis C virus-induced hepatocellular carcinoma. <i>MedComm</i> , 2020, 1, 178-187.	7.2	11
419	Comprehensive Bioinformatics Analysis of Key Methyltransferases and Demethylases for Histone Lysines in Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382098328.	1.9	7
420	Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. <i>Cancer Communications</i> , 2020, 40, 681-693.	9.2	40
421	Viruses in Cancers of the Digestive System: Active Contributors or Idle Bystanders?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8133.	4.1	11
422	Knowledge-based analyses reveal new candidate genes associated with risk of hepatitis B virus related hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 403.	2.6	6
423	Development and validation of 9-long Non-coding RNA signature to predicting survival in hepatocellular carcinoma. <i>Medicine (United States)</i> , 2020, 99, e20422.	1.0	18
424	Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. <i>Frontiers in Immunology</i> , 2020, 11, 1037.	4.8	55
425	Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. <i>Nutrients</i> , 2020, 12, 1576.	4.1	38
426	Long-term survival and recurrence after curative resection for hepatocellular carcinoma in patients with chronic hepatitis C virus infection: a multicenter observational study from China. <i>Hpb</i> , 2020, 22, 1793-1802.	0.3	6
427	High methylation levels of histone H3 lysine 9 associated with activation of hypoxia-inducible factor 1 \pm (HIF-1 \pm) predict patients' worse prognosis in human hepatocellular carcinomas. <i>Cancer Genetics</i> , 2020, 245, 17-26.	0.4	11

#	ARTICLE	IF	CITATIONS
428	CRISPR/CAS9-Mediated Antiviral Activity: A Tool to Combat Viral Infection. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2020, 30, 45-56.	0.9	2
429	Bis-indole alkaloid caulerpin from a new source <i>Sargassum platycarpum</i> : isolation, characterization, <i>in vitro</i> anticancer activity, binding with nucleobases by DFT calculations and MD simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 5137-5147.	3.5	13
430	Predicting miRNA targets for hepatocellular carcinoma with an integrated method. <i>Translational Cancer Research</i> , 2020, 9, 1752-1760.	1.0	2
431	LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2. <i>Annals of Hepatology</i> , 2020, 19, 535-540.	1.5	11
432	A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma. <i>Cell</i> , 2020, 182, 317-328.e10.	28.9	53
433	Protective and therapeutic effects of nanoliposomal quercetin on acute liver injury in rats. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 11.	2.4	16
434	Cellular UAP56 interacts with the HBx protein of the hepatitis B virus and is involved in viral RNA nuclear export in hepatocytes. <i>Experimental Cell Research</i> , 2020, 390, 111929.	2.6	7
435	Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 3057-3069.	2.8	23
436	Therapeutic effects of the PKR inhibitor C16 suppressing tumor proliferation and angiogenesis in hepatocellular carcinoma <i>in vitro</i> and <i>in vivo</i> . <i>Scientific Reports</i> , 2020, 10, 5133.	3.3	19
437	LncRNAs in HCV Infection and HCV-Related Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2255.	4.1	31
438	<p></p>YAP1 Promotes Tumor Invasion and Metastasis in Nasopharyngeal Carcinoma with Hepatitis B Virus Infection</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5629-5642.	2.0	4
439	Single nucleotide polymorphisms in telomere length-related genes are associated with hepatocellular carcinoma risk in the Chinese Han population. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093302.	3.2	4
440	Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents. <i>European Journal of Medicinal Chemistry</i> , 2020, 205, 112581.	5.5	7
441	USP9X promotes the progression of hepatocellular carcinoma by regulating beta-catenin. <i>Irish Journal of Medical Science</i> , 2020, 189, 865-871.	1.5	8
442	GP73 facilitates hepatitis B virus replication by repressing the NF- κ B signaling pathway. <i>Journal of Medical Virology</i> , 2020, 92, 3327-3335.	5.0	11
443	Nanocarrier-mediated antioxidant delivery for liver diseases. <i>Theranostics</i> , 2020, 10, 1262-1280.	10.0	44
444	The mutual interplay of gut microbiota, diet and human disease. <i>FEBS Journal</i> , 2020, 287, 833-855.	4.7	176
445	Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy. <i>Hepatology</i> , 2020, 72, 379-388.	7.3	12

#	ARTICLE	IF	CITATIONS
446	CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma. <i>Pharmacological Research</i> , 2020, 157, 104800.	7.1	23
447	DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. <i>Cancer Letters</i> , 2020, 483, 87-97.	7.2	31
448	CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma. <i>Cell Cycle</i> , 2020, 19, 1236-1252.	2.6	25
449	Identification of hepatitis B virus aetiologic antigens, HBx and PreS2, in diffuse large B-cell lymphoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 948-950.	2.0	7
450	RNA N6-Methyladenosine-Related Gene Contribute to Clinical Prognostic Impact on Patients With Liver Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 306.	2.3	9
451	The role of hepatitis C virus genotypes and core mutations in hepatocellular carcinoma in Cameroon. <i>Journal of Viral Hepatitis</i> , 2020, 27, 880-885.	2.0	1
452	Hepatocellular carcinoma in patients with no identifiable risk factors. <i>Hpb</i> , 2021, 23, 118-126.	0.3	4
453	Isolation, characterization, in vitro anticancer activity, dft calculations, molecular docking, bioactivity score, drug-likeness and admet studies of eight phytoconstituents from brown alga <i>sargassum platycarpum</i> . <i>Journal of Molecular Structure</i> , 2021, 1225, 129245.	3.6	43
454	Efficient Screening of Glycan-Specific Aptamers Using a Glycosylated Peptide as a Scaffold. <i>Analytical Chemistry</i> , 2021, 93, 956-963.	6.5	21
455	HBx represses WDR77 to enhance HBV replication by DDB1-mediated WDR77 degradation in the liver. <i>Theranostics</i> , 2021, 11, 8362-8378.	10.0	14
456	CRISPR-Cas9 in cancer therapeutics. <i>Progress in Molecular Biology and Translational Science</i> , 2021, 181, 129-163.	1.7	2
457	Laryngopharyngeal Reflux and Inflammatory Responses in Mucosal Barrier Dysfunction of the Upper Aerodigestive Tract. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 1291-1304.	3.5	15
458	Ring finger protein 152-dependent degradation of TSPAN12 suppresses hepatocellular carcinoma progression. <i>Cancer Cell International</i> , 2021, 21, 122.	4.1	7
459	Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma. <i>PLoS Computational Biology</i> , 2021, 17, e1008699.	3.2	5
460	Serum Soluble Fibrinogen-Like Protein 2 Represents a Novel Biomarker for Differentiation Between Acute and Chronic Egyptian Hepatitis B Virus-Infected Patients. <i>Journal of Interferon and Cytokine Research</i> , 2021, 41, 52-59.	1.2	5
461	MicroRNA-1271-5p alleviates the malignant development of hepatitis B virus-mediated liver cancer via binding to AQP5. <i>Molecular Medicine Reports</i> , 2021, 23, .	2.4	7
462	Prediction of hepatocellular carcinoma risk in patients with chronic liver disease from dynamic modular networks. <i>Journal of Translational Medicine</i> , 2021, 19, 122.	4.4	1
463	Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. <i>Aging</i> , 2021, 13, 11564-11594.	3.1	5

#	ARTICLE	IF	CITATIONS
464	A short overview of CRISPR-Cas technology and its application in viral disease control. <i>Transgenic Research</i> , 2021, 30, 221-238.	2.4	17
465	Interaction of Hepatitis B Virus X Protein with the Pregnane X Receptor Enhances the Synergistic Effects of Aflatoxin B1 and Hepatitis B Virus on Promoting Hepatocarcinogenesis. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	4
466	The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1217-1224.	1.2	8
467	Association between the Genetic Polymorphisms of CCL2, CCL5, CCL8, CCR2, and CCR5 with Chronic Hepatitis C Virus Infection in the Chinese Han Population. <i>Immunological Investigations</i> , 2021, , 1-16.	2.0	1
469	Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES). <i>Cancer Medicine</i> , 2021, 10, 3741-3755.	2.8	12
470	Antitumor Effects of Triterpenes in Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2021, 28, 2465-2484.	2.4	7
471	Solid-phase recombinase polymerase amplification using an extremely low concentration of a solution primer for sensitive electrochemical detection of hepatitis B viral DNA. <i>Biosensors and Bioelectronics</i> , 2021, 179, 113065.	10.1	24
472	Viruses and Bacteria Associated with Cancer: An Overview. <i>Viruses</i> , 2021, 13, 1039.	3.3	26
473	Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice. <i>Neoplasia</i> , 2021, 23, 529-538.	5.3	29
474	Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e686-e692.	1.6	11
475	Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review. <i>Viruses</i> , 2021, 13, 822.	3.3	3
476	The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. <i>Immunity</i> , 2021, 54, 1168-1185.e8.	14.3	40
477	Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. <i>Disease Markers</i> , 2021, 2021, 1-15.	1.3	25
478	CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death. <i>Frontiers in Oncology</i> , 2021, 11, 681683.	2.8	7
479	The Maturation of Tumor Suppressor miR-497 in Hepatocellular Carcinoma is Inhibited by Oncogenic circRNA SCARB1. <i>Cancer Management and Research</i> , 2021, Volume 13, 5751-5759.	1.9	2
480	The Protective Role of Etoricoxib Against Diethylnitrosamine/2-acetylaminofluorene- Induced Hepatocarcinogenesis in Wistar Rats: The Impact of NF- κ B/COX-2/PGE2 Signaling. <i>Current Molecular Pharmacology</i> , 2021, 15, 252-262.	1.5	7
481	Polyploidy control in hepatic health and disease. <i>Journal of Hepatology</i> , 2021, 75, 1177-1191.	3.7	19
482	Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study. <i>BMJ Open</i> , 2021, 11, e046115.	1.9	5

#	ARTICLE	IF	CITATIONS
483	Exosome-Based Vaccines: History, Current State, and Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 711565.	4.8	103
484	The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early-stage hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 5466-5474.	2.8	11
485	Hepatitis B virus infection and risk of gastric cancer: a systematic review and meta-analysis. <i>Minerva Gastroenterology</i> , 2024, 69, .	0.5	2
486	The Therapeutic Effect of Myrrh (<i>Commiphora molmol</i>) and Doxorubicin on Diethylnitrosamine Induced Hepatocarcinogenesis in Male Albino Rats. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2153-2163.	1.2	8
487	Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection: A Multicenter Observational Study. <i>Frontiers in Oncology</i> , 2021, 11, 700228.	2.8	6
489	Role of Virus-Induced Host Cell Epigenetic Changes in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8346.	4.1	35
490	Exploring the effect of Polyphyllin I on hepatitis B virus-related liver cancer through network pharmacology and in vitro experiments. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2021, 24, .	1.1	4
491	Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1729-1738.	1.8	1
492	Targeting ER stress in the hepatic tumor microenvironment. <i>FEBS Journal</i> , 2022, 289, 7163-7176.	4.7	23
493	Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 4831-4845.	3.3	7
494	Microbiota and Colorectal Cancer: From Gut to Bedside. <i>Frontiers in Pharmacology</i> , 2021, 12, 760280.	3.5	22
495	The emerging roles of m ⁶ A modification in liver carcinogenesis. <i>International Journal of Biological Sciences</i> , 2021, 17, 271-284.	6.4	27
497	Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. <i>Medicine (United States)</i> , 2020, 99, e20326.	1.0	8
498	TLR4 Influences Hepatitis B Virus Related Hepatocellular Carcinoma by Regulating the Wnt/ β -Catenin Pathway. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 469-479.	1.6	19
499	COX-2-765G>C Polymorphism Increases the Risk of Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e73213.	2.5	17
500	Replication of Genome Wide Association Studies on Hepatocellular Carcinoma Susceptibility Loci in a Chinese Population. <i>PLoS ONE</i> , 2013, 8, e77315.	2.5	37
501	Comparison of Hepatocellular Carcinoma miRNA Expression Profiling as Evaluated by Next Generation Sequencing and Microarray. <i>PLoS ONE</i> , 2014, 9, e106314.	2.5	74
502	Diffusion of Information throughout the Host Interactome Reveals Gene Expression Variations in Network Proximity to Target Proteins of Hepatitis C Virus. <i>PLoS ONE</i> , 2014, 9, e113660.	2.5	11

#	ARTICLE	IF	CITATIONS
503	Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients. PLoS ONE, 2015, 10, e0127524.	2.5	20
504	Association of Ghrelin Gene Polymorphisms and Serum Ghrelin Levels with the Risk of Hepatitis B Virus-Related Liver Diseases in a Chinese Population. PLoS ONE, 2015, 10, e0143069.	2.5	11
505	Liver Monocytes and Kupffer Cells Remain Transcriptionally Distinct during Chronic Viral Infection. PLoS ONE, 2016, 11, e0166094.	2.5	7
506	Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 Signaling. PLoS ONE, 2017, 12, e0170516.	2.5	47
507	HBV cccDNA and Its Potential as a Therapeutic Target. Journal of Clinical and Translational Hepatology, 2019, 7, 1-5.	1.4	22
509	HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive Health. , 2017, , 45-66.		18
510	eIF5B increases ASAP1 expression to promote HCC proliferation and invasion. Oncotarget, 2016, 7, 62327-62339.	1.8	24
511	Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. Oncotarget, 2016, 7, 86630-86647.	1.8	8
512	CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma. Oncotarget, 2017, 8, 18872-18884.	1.8	42
513	Novel indazole-based small compounds enhance TRAIL-induced apoptosis by inhibiting the MKK7-TIPRL interaction in hepatocellular carcinoma. Oncotarget, 2017, 8, 112610-112622.	1.8	12
514	Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma. Oncotarget, 2018, 9, 36057-36066.	1.8	12
515	Determination of candidate metabolite biomarkers associated with recurrence of HCV-related hepatocellular carcinoma. Oncotarget, 2018, 9, 6245-6258.	1.8	8
516	Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. Oncotarget, 2015, 6, 5666-5677.	1.8	54
517	SIP1 is a downstream effector of GADD45G in senescence induction and growth inhibition of liver tumor cells. Oncotarget, 2015, 6, 33636-33647.	1.8	14
518	Novel histone deacetylase inhibitor MPTOG009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget, 2016, 7, 402-417.	1.8	19
519	Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget, 2016, 7, 25087-25102.	1.8	60
520	Hepatitis B virus PreS2-mutant large surface antigen activates store-operated calcium entry and promotes chromosome instability. Oncotarget, 2016, 7, 23346-23360.	1.8	29
521	Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget, 2016, 7, 27838-27847.	1.8	25

#	ARTICLE	IF	CITATIONS
522	Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 54253-54262.	1.8	50
523	Tissue specificity of DNA damage response and tumorigenesis. <i>Cancer Biology and Medicine</i> , 2019, 16, 396-414.	3.0	32
524	The Potential Impacts of Tylophora Alkaloids and their Derivatives in Modulating Inflammation, Viral Infections, and Cancer. <i>Current Medicinal Chemistry</i> , 2019, 26, 4709-4725.	2.4	10
525	Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1839-1854.	2.1	7
526	Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 740-749.	1.7	2
527	Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 279.	8.9	70
528	Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 8822.	3.3	37
529	Exploitation of host clock gene machinery by hepatitis viruses B and C. <i>World Journal of Gastroenterology</i> , 2013, 19, 8902.	3.3	11
530	Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. <i>World Journal of Gastroenterology</i> , 2014, 20, 2913.	3.3	28
531	Occult hepatitis B virus and hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 5951.	3.3	53
532	Significance of viral status on occurrence of hepatitis B-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 5999.	3.3	11
533	Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. <i>World Journal of Gastroenterology</i> , 2014, 20, 7555.	3.3	40
534	Characterization of monocarboxylate transporter activity in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 11780.	3.3	31
535	Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases. <i>World Journal of Gastroenterology</i> , 2014, 20, 12381.	3.3	5
536	Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 3860.	3.3	20
537	IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation. <i>World Journal of Gastroenterology</i> , 2015, 21, 10137-10149.	3.3	39
538	Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 10584.	3.3	66
539	Hepatitis B and C virus-induced hepatitis: Apoptosis, autophagy, and unfolded protein response. <i>World Journal of Gastroenterology</i> , 2015, 21, 13225.	3.3	63

#	ARTICLE	IF	CITATIONS
540	Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 221.	3.3	42
541	Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World Journal of Gastroenterology, 2016, 22, 300.	3.3	20
542	Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 1497.	3.3	47
543	Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. World Journal of Gastroenterology, 2017, 23, 4538.	3.3	7
544	Multiple "omics"-data-based biomarker screening for hepatocellular carcinoma diagnosis. World Journal of Gastroenterology, 2019, 25, 4199-4212.	3.3	3
545	Multiple "omics"-data-based biomarker screening for hepatocellular carcinoma diagnosis. World Journal of Gastroenterology, 2019, 25, 4199-4212.	3.3	52
546	Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma. World Journal of Gastroenterology, 2020, 26, 2645-2656.	3.3	4
547	Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma (Review). Oncology Letters, 2019, 18, 4377-4384.	1.8	28
548	Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 70.	2.0	5
549	Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful?. World Journal of Hepatology, 2015, 7, 968.	2.0	78
550	New horizon for radical cure of chronic hepatitis B virus infection. World Journal of Hepatology, 2016, 8, 863.	2.0	13
551	Occult hepatitis B virus infection and surgical outcomes in non-B, non-C patients with curative resection for hepatocellular carcinoma. World Journal of Hepatology, 2017, 9, 1286-1295.	2.0	6
552	C-terminal truncated HBx reduces doxorubicin cytotoxicity via <i>ABCBI</i> upregulation in Huh-7 hepatocellular carcinoma cells. BMB Reports, 2019, 52, 330-335.	2.4	7
553	Targeting SHCBP1 Inhibits Cell Proliferation in Human Hepatocellular Carcinoma Cells. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5645-5650.	1.2	31
554	Hepatitis B Virus Gene Mutations and Hepatocarcinogenesis. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4509-4513.	1.2	22
555	Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization. Asian Pacific Journal of Cancer Prevention, 2016, 16, 8665-8670.	1.2	14
556	Genetic Variations in XRCC4 (rs1805377) and ATF6 (rs2070150) are not Associated with Hepatocellular Carcinoma in Thai Patients with Hepatitis B Virus Infection. Asian Pacific Journal of Cancer Prevention, 2016, 17, 591-595.	1.2	7
557	MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway. ELife, 2019, 8, .	6.0	32

#	ARTICLE	IF	CITATIONS
558	Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies. <i>Genes and Diseases</i> , 2023, 10, 151-164.	3.4	18
559	Association between viral infection other than human papillomavirus and risk of esophageal carcinoma: a comprehensive meta-analysis of epidemiological studies. <i>Archives of Virology</i> , 2022, 167, 1-20.	2.1	7
560	LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis. <i>Bioengineered</i> , 2021, 12, 10862-10877.	3.2	17
561	Effect of Differentially Expressed MicroRNAs 602 and 323-5p on Hepatitis C Virus Genotype 1b Viral Load in Infected Liver Cells. <i>Journal of Infectious Disease and Therapy</i> , 2014, 02, .	0.1	1
562	HBV/HCV Infection and Inflammation. <i>Journal of Genetic Syndromes & Gene Therapy</i> , 2014, 05, .	0.2	0
563	Cyclooxygenase-2 Promoter 765C Increase of Digestive Tract Cancer Risk in the Chinese Population: a Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 4563-4566.	1.2	5
564	Microbiome Analysis: Trends in Cancer Epidemiology, Challenges and Opportunities. <i>International Journal of Cancer Research and Molecular Mechanisms</i> , 2015, 1, .	0.2	0
566	Immunity to Oncogenic Viruses. , 2016, , 363-374.		0
567	Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2017, 37, 3207-3213.	1.1	8
568	Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. <i>Oncotarget</i> , 2017, 8, 93179-93185.	1.8	2
570	Activator protein-1 is a novel regulator of mesencephalic astrocyte-derived neurotrophic factor transcription. <i>Molecular Medicine Reports</i> , 2018, 18, 5765-5774.	2.4	1
571	An Expression Profile of Epithelial-Mesenchymal Transition-Related Genes in <i>Porphyromonas gingivalis</i>-Infected Ca9-22 Oral Squamous Cell Carcinoma Cells. <i>The Korean Journal of Oral and Maxillofacial Pathology</i> , 2019, 43, 11-16.	0.1	0
572	Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis <i>via</i> inducing cell cycle arrest and apoptosis. <i>World Journal of Gastroenterology</i> , 2019, 25, 6386-6403.	3.3	11
573	Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 3203-3210.	1.2	2
577	A NOTE ON HEPATITIS VIRUSES CAUSING CANCER IN HUMAN. <i>International Journal of Biological Innovations</i> , 2020, 02, 126-128.	0.6	1
579	In Silico Design of a Novel Multi-Epitope Peptide Vaccine Against Hepatocellular Carcinoma. <i>Letters in Drug Design and Discovery</i> , 2020, 17, 1164-1176.	0.7	1
580	Regulation of gene expression in HBV- and HCV-related hepatocellular carcinoma: integrated GWRS and GWGS analyses. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 4038-50.	1.3	3
581	MDM2 SNP309 variation confers the susceptibility to hepatocellular cancer: a meta-analysis based on 4271 subjects. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 5822-30.	1.3	3

#	ARTICLE	IF	CITATIONS
582	Multifunctional DDX3: dual roles in various cancer development and its related signaling pathways. American Journal of Cancer Research, 2016, 6, 387-402.	1.4	33
583	Emerging roles of FGF signaling in hepatocellular carcinoma. Translational Cancer Research, 2016, 5, 1-6.	1.0	21
584	E2F1 transactivates IQGAP3 and promotes proliferation of hepatocellular carcinoma cells through IQGAP3-mediated PKC-alpha activation. American Journal of Cancer Research, 2019, 9, 285-299.	1.4	5
585	HBV integrated genomic characterization revealed hepatocyte genomic alterations in HBV-related hepatocellular carcinomas. Molecular and Clinical Oncology, 2020, 13, 79.	1.0	0
586	Long non-coding RNAs (LncRNAs), viral oncogenomics, and aberrant splicing events: therapeutics implications. American Journal of Cancer Research, 2021, 11, 866-883.	1.4	3
587	First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterology, 2021, 21, 443.	2.0	3
588	Synthesis and evaluation of novel quinazolinone derivatives as potential anti-HCC agents. Chemistry and Biodiversity, 2021, , .	2.1	1
589	Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: A prospective cohort study. International Journal of Cancer, 2022, 150, 1018-1028.	5.1	27
590	Type I interferons: One stone to concurrently kill two birds, viral infections and cancers. Current Research in Virological Science, 2021, 2, 100014.	3.5	5
591	HBV integrated genomic characterization revealed hepatocyte genomic alterations in HBV-related hepatocellular carcinomas. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	1
592	A Prognostic Nomogram for Hepatocellular Carcinoma Based on Wound Healing and Immune Checkpoint Genes. Journal of Clinical and Translational Hepatology, 2022, 10, 891-900.	1.4	2
593	Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation. Frontiers in Pharmacology, 2021, 12, 805318.	3.5	4
594	Anti-Hepatocellular Carcinoma Effect and Molecular Mechanism of the Estrogen Signaling Pathway. Frontiers in Oncology, 2021, 11, 763539.	2.8	10
595	An automated and mobile magnetoresistive biosensor system for early hepatocellular carcinoma diagnosis. Biosensors and Bioelectronics, 2022, 202, 113982.	10.1	18
596	Monitoring Clinical Pathological Grading of Hepatocellular Carcinoma Using MicroRNA-Guided Semiconducting Polymer Dots. ACS Applied Materials & Interfaces, 2022, 14, 7717-7730.	8.0	5
597	Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States. Alimentary Pharmacology and Therapeutics, 2022, 55, 828-835.	3.7	9
598	The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: Current scenario and future anticipation. Journal of Cellular Biochemistry, 2022, 123, 1607-1623.	2.6	7
599	A novel hydrophilic MOFs-303-functionalized magnetic probe for the highly efficient analysis of N-linked glycopeptides. Journal of Materials Chemistry B, 2022, 10, 2011-2018.	5.8	12

#	ARTICLE	IF	CITATIONS
600	Ellagic Acid: A Review on Its Natural Sources, Chemical Stability, and Therapeutic Potential. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-24.	4.0	80
601	The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model. <i>BMC Cancer</i> , 2022, 22, 185.	2.6	0
602	Innate and Adaptive Immunopathogenesises in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1255.	3.7	24
603	Multiomics Analysis of Endocytosis upon HBV Infection and Identification of SCAMP1 as a Novel Host Restriction Factor against HBV Replication. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2211.	4.1	3
604	Focusing on Mechanoregulation Axis in Fibrosis: Sensing, Transduction and Effecting. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 804680.	3.5	7
605	Gut Microbiome Dysbiosis in Alcoholism: Consequences for Health and Recovery. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 840164.	3.9	19
606	Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. <i>BMC Cancer</i> , 2022, 22, 287.	2.6	17
607	A predictive model incorporating inflammation markers for high-grade surgical complications following liver resection for hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 845-852.	1.4	4
608	Virus Detection: From State-of-the-Art Laboratories to Smartphone-Based Point-of-Care Testing. <i>Advanced Science</i> , 2022, 9, e2105904.	11.2	66
609	The Emerging Role of Hedgehog Signaling in Viral Infections. <i>Frontiers in Microbiology</i> , 2022, 13, 870316.	3.5	4
610	Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 101-127.	4.5	17
611	Hepatitis C virus core protein inhibits hepatitis B virus replication by downregulating HBx levels via Siah-1-mediated proteasomal degradation during coinfection. <i>Journal of General Virology</i> , 2021, 102, .	2.9	2
612	De novo identification of maximally deregulated subnetworks based on multi-omics data with DeRegNet. <i>BMC Bioinformatics</i> , 2022, 23, 139.	2.6	1
613	Long-Term Survival Impact of High-Grade Complications after Liver Resection for Hepatocellular Carcinoma: A Retrospective Single-Centre Cohort Study. <i>Medicina (Lithuania)</i> , 2022, 58, 534.	2.0	1
620	Frequency distribution and ten-year survival rate of patients with different malignant liver lesions in Iran -Z. <i>Journal of Advanced Pharmacy Education and Research</i> , 2022, 12, 71-75.	1.1	1
622	Circ_MTM1 knockdown inhibits the progression of HBV-related liver fibrosis via regulating IL7R expression through targeting miR-122-5p.. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 2199-2211.	0.0	0
623	Long non-coding RNAs in virus-related cancers. <i>Reviews in Medical Virology</i> , 2022, 32, .	8.3	5
624	Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D. <i>Antiviral Research</i> , 2022, 203, 105348.	4.1	3

#	ARTICLE	IF	CITATIONS
626	Spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation in hepatitis B-related liver cancer. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 573-589.	4.4	1
627	Recent Progress on the Role of Fibronectin in Tumor Stromal Immunity and Immunotherapy. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2494-2505.	2.1	3
628	Targeted Proteins Reveal Cathepsin D as a Novel Biomarker in Differentiating Hepatocellular Carcinoma from Cirrhosis and Other Liver Cancers. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2017-2025.	1.2	2
629	Hepatitis B virus X protein and hepatitis C virus core protein cooperate to repress E-cadherin expression via DNA methylation. <i>Heliyon</i> , 2022, 8, e09881.	3.2	0
630	Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 2350-2371.	9.4	28
631	Study of golgi protein-7 levels associated cirrhosis in patients with infections hepatitis B virus. <i>International Journal of Health Sciences</i> , 0, , 6211-6220.	0.1	0
632	Clinical spectrum of rectal cancer identifies hallmarks of early-onset patients and next-generation treatment strategies. <i>Cancer Medicine</i> , 2023, 12, 3433-3441.	2.8	4
633	Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 1185-1196.	3.4	9
634	Contribution of DNA methylation to the risk of hepatitis C virus-associated hepatocellular carcinoma: A meta-analysis. <i>Pathology Research and Practice</i> , 2022, 238, 154136.	2.3	1
635	Exploration of immune infiltration and feature genes in viral hepatitis-associated liver fibrosis using transcriptome data. <i>Annals of Translational Medicine</i> , 2022, 10, 1051-1051.	1.7	2
636	A Web-Based Prediction Model for Estimating the Probability of Post-hepatectomy Major Complications in Patients with Hepatocellular Carcinoma: A Multicenter Study from a Hepatitis B Virus-Endemic Area. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 2082-2092.	1.7	1
637	CDC20 May Serve as a Potential Biomarker-Based Risk Score System in Predicting the Prognosis of Patients with Hepatocellular Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-21.	4.0	2
638	Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B. <i>Biomedicines</i> , 2022, 10, 2210.	3.2	5
639	Hepatitis B virus promotes hepatocellular carcinoma development by activating GP73 to repress the innate immune response. <i>Infectious Agents and Cancer</i> , 2022, 17, .	2.6	2
640	Imunopatogenesis Karsinoma Hepatoselular. , 2022, 1, 318-324.		0
641	Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2022, 18, 3769-3782.	2.4	11
642	Does global warming increase the risk of liver cancer in Australia? Perspectives based on spatial variability. <i>Science of the Total Environment</i> , 2023, 859, 160412.	8.0	1
643	Sex steroid axes in determining male predominance in hepatocellular carcinoma. <i>Cancer Letters</i> , 2023, 555, 216037.	7.2	5

#	ARTICLE	IF	CITATIONS
644	CircRNAs in hepatocellular carcinoma: characteristic, functions and clinical significance. International Journal of Medical Sciences, 2022, 19, 2033-2043.	2.5	5
645	An Update on the Metabolic Landscape of Oncogenic Viruses. Cancers, 2022, 14, 5742.	3.7	3
646	Integrative analysis indicates the prognostic value of circadian rhythm disruption in liver cancer: Potential for therapeutic targeting. Frontiers in Immunology, 0, 13, .	4.8	1
647	A dual-targeting near-infrared biomimetic drug delivery system for HBV treatment. Journal of Medical Virology, 2023, 95, .	5.0	3
648	Unraveling the Molecular Mechanisms Involved in HCV-Induced Carcinogenesis. Viruses, 2022, 14, 2762.	3.3	5
649	Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma. Frontiers in Endocrinology, 0, 13, .	3.5	0
650	Peripheral B cells from patients with hepatitis C virus-associated lymphoma exhibit clonal expansion and an anergic-like transcriptional profile. IScience, 2023, 26, 105801.	4.1	1
651	A Systemic Inflammation Response Score for Prognostic Prediction in Hepatocellular Carcinoma Patients After Hepatectomy. Journal of Inflammation Research, 0, Volume 15, 6869-6881.	3.5	1
652	<sc>MiR</sc>â€155 regulates <sc>M2</sc> polarization of hepatitis B virusâ€infected tumourâ€associated macrophages which in turn regulates the malignant progression of hepatocellular carcinoma. Journal of Viral Hepatitis, 2023, 30, 417-426.	2.0	2
653	Epigenetic modifications and regulation in infection. , 2023, , 181-209.		0
654	Hepatocellular carcinoma associated with hepatitis B virus and environmental factors. , 2023, , 5-27.		0
655	Hepatosellâ¼ler kanser nedeniyle tek merkezde yap±lan karaciÄyer nakli sonuÅlar±. Konuralp Tıp Dergisi, 0, , .	0.3	0
656	Development of Prognostic Features of Hepatocellular Carcinoma Based on Metabolic Gene Classification and Immune and Oxidative Stress Characteristic Analysis. Oxidative Medicine and Cellular Longevity, 2023, 2023, 1-29.	4.0	1
657	Comparison of anti-tumor activities and underlying mechanisms of glucuronomannan oligosaccharides and its sulfated derivatives on the hepatocarcinoma Huh7.5 cells. Biochemical and Biophysical Research Communications, 2023, 652, 103-111.	2.1	1
658	<sc>miR</sc> â€144â€3p represses hepatocellular carcinoma progression by affecting cell aerobic glycolysis via <sc>FOXK1</sc>. International Journal of Experimental Pathology, 0, , .	1.3	5
659	Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy. Cancer Gene Therapy, 2023, 30, 936-954.	4.6	15
660	Celastrol attenuates hepatitis C virus translation and inflammatory response in mice by suppressing heat shock protein 90Î². Acta Pharmacologica Sinica, 2023, 44, 1637-1648.	6.1	4
661	<sc>HBx</sc> downregulated decorin and decorinâ€derived peptides inhibit the proliferation and tumorigenicity of hepatocellular carcinoma cells. FASEB Journal, 2023, 37, .	0.5	1

#	ARTICLE	IF	CITATIONS
662	Tumours and Tumour-Like Lesions. , 2024, , 842-946.		1
663	Identification of Liver Cancer Driver Mutations from COSMIC Data. International Journal of Cancer Management, 2023, 16, .	0.4	0
664	Bioinformatics and network pharmacology-based study to elucidate the multi-target pharmacological mechanism of the indigenous plants of Medina valley in treating HCV-related hepatocellular carcinoma. Saudi Pharmaceutical Journal, 2023, , .	2.7	3
665	HBV precore G1896A mutation promotes growth of hepatocellular carcinoma cells by activating ERK/MAPK pathway. Virologica Sinica, 2023, 38, 680-689.	3.0	2
666	Pathogenesis of Oncoviruses: A Systemic Review. Microbiology and Biotechnology Letters, 2023, 51, 135-146.	0.4	0
667	Perioperative predictors of outcome of hepatectomy for HBV-related hepatocellular carcinoma. Frontiers in Oncology, 0, 13, .	2.8	0
668	Imaging Investigation of Hepatocellular Carcinoma Progress via Monitoring \hat{I}^3 -Glutamyltranspeptidase Level with a Near-Infrared Fluorescence/Photoacoustic Bimodal Probe. Analytical Chemistry, 2023, 95, 14235-14243.	6.5	2
669	TRB CDR3 chemical complementarity with HBV epitopes correlates with increased hepatocellular carcinoma, disease-free survival. Journal of Medical Virology, 2023, 95, .	5.0	0
670	Serum vitamin D deficiency is associated with increased risk of \hat{I}^3 T cell exhaustion in $\langle scp \rangle$ HBV $\langle /scp \rangle$ -infected patients. Immunology, 2024, 171, 31-44.	4.4	0
671	Zebrafish as a Useful Model System for Human Liver Disease. Cells, 2023, 12, 2246.	4.1	2
672	Comparison of clinicopathologic characteristics among patients with HBV-positive, HCV-positive and Non-B Non-C hepatocellular carcinoma after hepatectomy: a systematic review and meta-analysis. BMC Gastroenterology, 2023, 23, .	2.0	1
673	Exploring the pharmacological mechanism of Wuzhuyu decoction on hepatocellular carcinoma using network pharmacology. World Journal of Clinical Cases, 0, 11, 6327-6343.	0.8	1
674	Knowledge and Attitude of Undergraduate Health Professions Students towards Hepatitis B and C. Scientific World Journal, The, 2023, 2023, 1-9.	2.1	1
675	Activation of AIM2 by hepatitis B virus results in antiviral immunity that suppresses hepatitis C virus during coinfection. Journal of Virology, 2023, 97, .	3.4	1
676	An update on the global trends in the burden of primary liver cancers. Journal of Surgical Oncology, 2023, 128, 972-979.	1.7	0
677	Impact of hepatitis B virus infection on the risk of gallbladder polyps: a cohort study. Korean Journal of Internal Medicine, 0, , .	1.7	0
678	Prediction and surveillance of de novo HCC in patients with compensated advanced chronic liver disease after hepatitis C virus eradication with direct antiviral agents. Frontiers in Virology, 0, 3, .	1.4	0
679	Vaccine escape challenges virus prevention: The example of two vaccine-preventable oncogenic viruses. Journal of Medical Virology, 2023, 95, .	5.0	2

#	ARTICLE	IF	CITATIONS
680	Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss. <i>Gut</i> , 0, , gutjnl-2023-330577.	12.1	2
681	Multiply robust estimation of natural indirect effects with multiple ordered mediators. <i>Statistics in Medicine</i> , 2024, 43, 656-673.	1.6	0
682	Integrative Analysis of the Role of TP53 in Human Pan-Cancer. <i>Current Issues in Molecular Biology</i> , 2023, 45, 9606-9633.	2.4	0
683	Impact of amino acid substitutions in hepatitis C virus core region on the severe oxidative stress. <i>Free Radical Biology and Medicine</i> , 2024, 212, 199-206.	2.9	0
684	Liver organoids and their application in liver cancer research. <i>Regenerative Therapy</i> , 2024, 25, 128-137.	3.0	0
685	Inverse association between type 2 diabetes and hepatocellular carcinoma in East Asian populations. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
686	Immunological pathways in viral hepatitis-induced hepato-cellular carcinoma. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2024, 53, 64-72.	0.3	0
687	Educational Case: Hepatocellular carcinoma. <i>Academic Pathology</i> , 2024, 11, 100108.	1.1	0
688	Network-base approaches to identify therapeutic biomarkers in hepatocellular carcinoma and search for drug hunting utilizing molecular dynamics simulations. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-17.	3.5	0